π¬ Pharmidex is proud to contribute to new research!
June 10, 2025
We’re excited to announce our involvement in the recent publication:
"Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4"
π
https://pubmed.ncbi.nlm.nih.gov/40245851/
π
https://www.pharmidex.com/publications-by-pharmidex
Dr.
Radhakrishnan Venkatasamy, our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential.
This reflects
Pharmidex’s commitment to advancing therapies through expert science and collaboration.

#Pharmidex #DrugDiscovery #Inflammation #Ensifentrine

Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN

Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! π https://lnkd.in/ev7TW7WG

We're excited to announce the integration of the Sysmex CA-660 semi-automated Coagulation Analyzer into our lab infrastructure. This compact yet powerful instrument brings clinical-grade coagulation testing to our preclinical workflows, enabling: β
High-precision clotting, chromogenic & immunoassays β
Low sample & reagent volume needs ideal for preclinical models β
Robust data reproducibility for decision-critical insights β
Easy-to-use interface for rapid turnaround With the CA-660, Pharmidex is further enhancing its capacity to deliver accurate, consistent and fast coagulation studies, a key component in safety pharmacology, clinical pathology and drug development. This system supports our mission to provide high-quality bioanalytical, DMPK and toxicology services to our partners in biotech and pharma.